8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Nov 12, 2025·SEC
Bolt Biotherapeutics, Inc.(BOLT)Earnings, Financials & Key Ratios
BOLT•NASDAQ
Price updated Jun 19, 2026
AboutBolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.Show more
- Revenue$8M
- EBITDA-$33M+53.5%
- Net Income-$33M+47.1%
- EPS (Diluted)-17.85-981.8%
- Gross Margin80.62%-19.4%
- EBITDA Margin-430.7%+53.5%
- Operating Margin-450.07%+52.6%
- Net Margin-433.74%+47.2%
- ROE-79.75%-7.4%
BOLT Key Insights
Bolt Biotherapeutics, Inc. (BOLT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 101.6%
- ✓Share count reduced 95.1% through buybacks
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BOLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BOLT Price & Volume
Bolt Biotherapeutics, Inc. (BOLT) stock price & volume — 10-year historical chart
Loading chart...
BOLT Growth Metrics
Bolt Biotherapeutics, Inc. (BOLT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years101.61%
3 Years10.33%
TTM78.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM53.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-851.5%
Return on Capital
10 Years-74.07%
5 Years-51.34%
3 Years-54.07%
Last Year-52.44%
BOLT Recent Earnings
Bolt Biotherapeutics, Inc. (BOLT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$4.31-51.2%
$2.85
Rev
$26,000-98.3%
$2M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$3.84+10.7%
$4.30
Rev
$3M+275.0%
$666,667
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$3.72+26.6%
$5.07
Rev
$2M+164.3%
$820,800
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$4.46+30.3%
$6.40
Rev
$2M+113.3%
$845,800
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $4.31vs $2.85-51.2% | $26,000vs $2M-98.3% |
| Q2 2026 | Mar 12, 2026 | $3.84vs $4.30+10.7% | $3Mvs $666,667+275.0% |
| Q4 2025 | Nov 12, 2025 | $3.72vs $5.07+26.6% | $2Mvs $820,800+164.3% |
| Q3 2025 | Aug 14, 2025 | $4.46vs $6.40+30.3% | $2Mvs $845,800+113.3% |
Based on last 12 quarters of dataView full earnings history →
BOLT Peer Comparison
Bolt Biotherapeutics, Inc. (BOLT) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare BOLT vs Peers
Bolt Biotherapeutics, Inc. (BOLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BOLT Income Statement
Bolt Biotherapeutics, Inc. (BOLT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 215K | 231K | 1.26M | 5.73M | 7.88M | 7.69M | 7.7M | 6.5M |
Revenue Growth % | - | - | 7.44% | 445.45% | 354.68% | 37.48% | -2.36% | 0.07% | 78.64% |
Cost of Goods Sold | 302K | 0 | 40.36M | 75.66M | 73.12M | 61.54M | 0 | 1.49M | 203K |
COGS % of Revenue | - | - | 17470.56% | 6004.37% | 1276.37% | 781.39% | - | 19.38% | - |
Gross Profit | -302K▲ 0% | 215K▲ 171.2% | -40.13M▼ 18763.3% | -74.39M▼ 85.4% | -67.39M▲ 9.4% | -53.67M▲ 20.4% | 7.69M▲ 114.3% | 6.2M▼ 19.3% | 6.3M▲ 0% |
Gross Margin % | - | 100% | -17370.56% | -5904.37% | -1176.37% | -681.39% | 100% | 80.62% | 96.88% |
Gross Profit Growth % | - | 171.19% | -18763.26% | -85.4% | 9.41% | 20.37% | 114.33% | -19.32% | - |
Operating Expenses | 11.63M | 31.18M | 9.06M | 18.39M | 22.93M | 22.53M | 80.74M | 40.84M | 36.41M |
OpEx % of Revenue | - | 14504.19% | 3920.35% | 1459.76% | 400.19% | 286.06% | 1049.91% | 530.7% | - |
Selling, General & Admin | 2.21M | 5.18M | 9.06M | 18.39M | 22.93M | 22.53M | 18.46M | 13.79M | 12.77M |
SG&A % of Revenue | - | 2410.23% | 3920.35% | 1459.76% | 400.19% | 286.06% | 240.01% | 179.27% | - |
Research & Development | 9.42M | 26M | 40.36M | 75.66M | 73.12M | 61.54M | 57.47M | 28.53M | 23.65M |
R&D % of Revenue | - | 12093.95% | 17470.56% | 6004.37% | 1276.37% | 781.39% | 747.32% | 370.8% | - |
Other Operating Expenses | -153K | 0 | -40.36M | -75.66M | -73.12M | -61.54M | 4.81M | -1.49M | 0 |
Operating Income | -11.63M▲ 0% | -30.97M▼ 166.3% | -49.18M▼ 58.8% | -92.79M▼ 88.7% | -90.32M▲ 2.7% | -76.2M▲ 15.6% | -73.05M▲ 4.1% | -34.63M▲ 52.6% | -30.12M▲ 0% |
Operating Margin % | - | -14404.19% | -21290.91% | -7364.13% | -1576.56% | -967.45% | -949.91% | -450.07% | -463.44% |
Operating Income Growth % | - | -166.31% | -58.81% | -88.66% | 2.66% | 15.64% | 4.13% | 52.59% | - |
EBITDA | -11.33M | -30.63M | -48.57M | -91.59M | -88.66M | -74.34M | -71.27M | -33.14M | -29.02M |
EBITDA Margin % | - | -14248.37% | -21026.41% | -7269.44% | -1547.48% | -943.91% | -926.75% | -430.7% | -446.59% |
EBITDA Growth % | - | -170.45% | -58.55% | -88.58% | 3.21% | 16.14% | 4.14% | 53.5% | 55.42% |
D&A (Non-Cash Add-back) | 302K | 335K | 611K | 1.19M | 1.67M | 1.85M | 1.78M | 1.49M | 1.09M |
EBIT | -11.59M | -30.97M | -49.18M | -92.79M | -90.32M | -76.2M | -68.24M | -34.63M | -30.12M |
Net Interest Income | 0 | 524K | 199K | 281K | 2.22M | 7M | 5.25M | 2.5M | 1.72M |
Interest Income | 193K | 524K | 199K | 281K | 2.22M | 7M | 5.25M | 2.5M | 1.72M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 40K | 482K | -11.55M | -5.8M | 2.22M | 7M | 9.93M | 1.26M | 539K |
Pretax Income | -11.59M▲ 0% | -30.49M▼ 163.1% | -60.73M▼ 99.2% | -98.59M▼ 62.3% | -88.1M▲ 10.6% | -69.2M▲ 21.5% | -63.12M▲ 8.8% | -33.38M▲ 47.1% | -29.58M▲ 0% |
Pretax Margin % | - | -14180% | -26289.18% | -7824.68% | -1537.76% | -878.58% | -820.78% | -433.74% | -455.15% |
Income Tax | 40K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -11.59M▲ 0% | -30.49M▼ 163.1% | -60.73M▼ 99.2% | -98.59M▼ 62.3% | -88.1M▲ 10.6% | -69.2M▲ 21.5% | -63.12M▲ 8.8% | -33.38M▲ 47.1% | -29.58M▲ 0% |
Net Margin % | - | -14180% | -26289.18% | -7824.68% | -1537.76% | -878.58% | -820.78% | -433.74% | -455.15% |
Net Income Growth % | - | -163.07% | -99.19% | -62.35% | 10.64% | 21.45% | 8.79% | 47.12% | 53.3% |
Net Income (Continuing) | -11.59M | -30.49M | -60.73M | -98.59M | -88.1M | -69.2M | -63.12M | -33.38M | -29.58M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.96▲ 0% | -3.75▲ 37.1% | -1.99▲ 46.9% | -2.79▼ 40.2% | -2.30▲ 17.6% | -1.83▲ 20.4% | -1.65▲ 9.8% | -17.85▼ 981.8% | -15.82▲ 0% |
EPS Growth % | - | 37.08% | 46.93% | -40.2% | 17.56% | 20.43% | 9.84% | -981.82% | -851.5% |
EPS (Basic) | -5.96 | -3.75 | -1.99 | -2.79 | -2.30 | -1.83 | -1.65 | -17.85 | - |
Diluted Shares Outstanding | 1.94M | 8.01M | 36.25M | 37.4M | 37.36M | 37.81M | 38.18M | 1.87M | 1.87M |
Basic Shares Outstanding | 1.94M | 8.01M | 36.25M | 37.4M | 37.36M | 37.81M | 38.18M | 1.87M | 1.87M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BOLT Balance Sheet
Bolt Biotherapeutics, Inc. (BOLT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.1M | 35.9M | 25.36M | 189.16M | 172.75M | 105.71M | 50.81M | 30.26M | 25.75M |
Cash & Short-Term Investments | 13.63M | 34.83M | 22.84M | 186.22M | 168.89M | 102.19M | 47.32M | 27.5M | 22.89M |
Cash Only | 13.63M | 34.83M | 5.54M | 27.38M | 9.24M | 10.81M | 7.21M | 11.7M | 11.61M |
Short-Term Investments | 0 | 0 | 17.3M | 158.84M | 159.64M | 91.38M | 40.12M | 15.8M | 11.28M |
Accounts Receivable | 0 | 300K | 0 | 200K | 0 | 0 | 1.17M | 973K | 0 |
Days Sales Outstanding | - | 509.3 | - | 57.94 | - | - | 55.3 | 46.15 | 26.97 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 2.74M | 3.86M | 3.52M | 1.29M | 1.78M | 2.86M |
Total Non-Current Assets | 1.88M | 12.55M | 21.18M | 118.56M | 55.06M | 54.08M | 48.82M | 26.49M | 22.27M |
Property, Plant & Equipment | 1.44M | 11.52M | 16.38M | 30.6M | 28.52M | 24.08M | 24.89M | 20.48M | 19.61M |
Fixed Asset Turnover | - | 0.02x | 0.01x | 0.04x | 0.20x | 0.33x | 0.31x | 0.38x | 0.31x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 584K | 0 | 86.91M | 23.94M | 26.41M | 22.88M | 4.34M | 25.99M |
Other Non-Current Assets | 433K | 446K | 4.8M | 1.04M | 2.59M | 3.59M | 1.04M | 1.68M | 1.65M |
Total Assets | 15.97M▲ 0% | 48.45M▲ 203.3% | 46.54M▼ 3.9% | 307.72M▲ 561.2% | 227.81M▼ 26.0% | 159.78M▼ 29.9% | 99.63M▼ 37.6% | 56.75M▼ 43.0% | 48.03M▲ 0% |
Asset Turnover | - | 0.00x | 0.00x | 0.00x | 0.03x | 0.05x | 0.08x | 0.14x | 0.11x |
Asset Growth % | - | 203.27% | -3.93% | 561.16% | -25.97% | -29.86% | -37.65% | -43.04% | -166.81% |
Total Current Liabilities | 2.75M | 8.66M | 11.26M | 21.33M | 23.12M | 20.46M | 15.86M | 8.44M | 7.34M |
Accounts Payable | 892K | 2.1M | 1.6M | 3.57M | 3.59M | 2.99M | 1.51M | 1.44M | 1.74M |
Days Payables Outstanding | 1.08K | - | 14.45 | 17.24 | 17.94 | 17.72 | - | 353.25 | 2.94K |
Short-Term Debt | 0 | 0 | 0 | 2.5M | 0 | 0 | 0 | 2.83M | 2.96M |
Deferred Revenue (Current) | 0 | 599K | 1.5M | 2.87M | 1.99M | 2.2M | 3.02M | 449K | 5.5M |
Other Current Liabilities | 0 | 1.41M | 3.78M | 7.5M | 4.8M | 6.67M | 4.2M | 3.72M | 2.02M |
Current Ratio | 5.12x | 4.15x | 2.25x | 8.87x | 7.47x | 5.17x | 3.20x | 3.59x | 3.51x |
Quick Ratio | 5.12x | 4.15x | 2.25x | 8.87x | 7.47x | 5.17x | 3.20x | 3.59x | 3.51x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -2.92K |
Total Non-Current Liabilities | 29.16M | 85.64M | 140.22M | 36.27M | 33.18M | 26.59M | 26.58M | 21.81M | 20.86M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.35M |
Capital Lease Obligations | 0 | 7.09M | 9.38M | 21.85M | 20.22M | 17.44M | 22.96M | 20.13M | 62.65M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29.16M | 77.58M | 130.85M | 210K | 42K | 43K | 0 | 132K | 1.51M |
Total Liabilities | 31.92M | 94.29M | 151.49M | 57.6M | 56.3M | 47.04M | 42.43M | 30.24M | 28.2M |
Total Debt | 40K | 10.19M | 10.88M | 24.36M | 22.61M | 20.22M | 25.21M | 22.96M | 22.31M |
Net Debt | -13.59M | -24.64M | 5.33M | -3.03M | 13.37M | 9.41M | 18M | 11.26M | 10.7M |
Debt / Equity | - | - | - | 0.10x | 0.13x | 0.18x | 0.44x | 0.87x | 1.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.77x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.37x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -15.94M▲ 0% | -45.85M▼ 187.6% | -104.95M▼ 128.9% | 250.12M▲ 338.3% | 171.51M▼ 31.4% | 112.74M▼ 34.3% | 57.2M▼ 49.3% | 26.5M▼ 53.7% | 19.82M▲ 0% |
Equity Growth % | - | -187.56% | -128.91% | 338.33% | -31.43% | -34.26% | -49.27% | -53.66% | -221.51% |
Book Value per Share | -8.20 | -5.72 | -2.90 | 6.69 | 4.59 | 2.98 | 1.50 | 14.17 | 10.60 |
Total Shareholders' Equity | -15.94M | -45.85M | -104.95M | 250.12M | 171.51M | 112.74M | 57.2M | 26.5M | 19.82M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 1K | 0 | 0 | 0 |
Retained Earnings | -17.18M | -47.67M | -108.4M | -206.99M | -295.09M | -364.29M | -427.4M | -460.78M | -468.02M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -321K | -919K | 37K | 97K | -21K | -11K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BOLT Cash Flow Statement
Bolt Biotherapeutics, Inc. (BOLT) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.87M | -26.34M | -47.31M | -57.07M | -76.5M | -69.53M | -61.29M | -39.85M | -34.51M |
Operating CF Margin % | - | -12252.56% | -20479.65% | -4529.05% | -1335.38% | -882.75% | -797% | -517.87% | - |
Operating CF Growth % | - | -166.85% | -79.58% | -20.63% | -34.06% | 9.12% | 11.85% | 34.98% | 161.24% |
Net Income | -11.59M | -30.49M | -60.73M | -98.59M | -88.1M | -69.2M | -63.12M | -33.38M | -29.58M |
Depreciation & Amortization | 302K | 335K | 611K | 1.19M | 1.67M | 1.85M | 1.78M | 1.29M | 1.09M |
Stock-Based Compensation | 123K | 508K | 1.42M | 8.5M | 9.58M | 9.22M | 7.41M | 2.78M | 2.07M |
Deferred Taxes | 0 | 0 | 34K | 2.76M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 153K | 1.04M | 13.64M | 8.56M | 3.41M | -1.54M | 1.08M | 1.57M | 2.58M |
Working Capital Changes | 1.14M | 2.27M | -2.28M | 20.51M | -3.06M | -9.86M | -8.44M | -12.12M | -10.68M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 2.88M | 6.68M | 2.77M | -3.41M | 0 | 0 | 0 |
Cash from Investing | -290K | -508K | -20.59M | -232.2M | 57.86M | 71.04M | 57.58M | 44.3M | 37.67M |
Capital Expenditures | -290K | -508K | -3.26M | -2.34M | -1.95M | -206K | -41K | -72K | -72K |
CapEx % of Revenue | - | 236.28% | 1412.12% | 185.56% | 34.09% | 2.62% | 0.53% | 0.94% | 1.11% |
Acquisitions | 0 | 0 | 17.33M | 229.86M | -59.81M | 0 | 148K | 963K | 994K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -17.33M | -229.86M | 59.81M | 0 | 0 | 0 | -963K |
Cash from Financing | 19.09M | 48.63M | 39.6M | 311.11M | 503K | 253K | 108K | 19K | 25K |
Debt Issued (Net) | -39K | -40K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 48.67M | 41.56M | 311.11M | 503K | 253K | 108K | 19K | 25K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 19.13M | 0 | -1.97M | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | 8.93M▲ 0% | 21.78M▲ 143.8% | -28.3M▼ 230.0% | 21.84M▲ 177.2% | -18.14M▼ 183.1% | 1.77M▲ 109.7% | -3.6M▼ 304.1% | 4.47M▲ 224.0% | 3.19M▲ 0% |
Free Cash Flow | -10.16M▲ 0% | -26.85M▼ 164.2% | -50.57M▼ 88.3% | -59.4M▼ 17.5% | -78.46M▼ 32.1% | -69.73M▲ 11.1% | -61.33M▲ 12.0% | -39.92M▲ 34.9% | -26.56M▲ 0% |
FCF Margin % | - | -12488.84% | -21891.77% | -4714.6% | -1369.47% | -885.36% | -797.53% | -518.8% | -408.63% |
FCF Growth % | - | -164.23% | -88.34% | -17.47% | -32.07% | 11.12% | 12.05% | 34.91% | 54.17% |
FCF per Share | -5.23 | -3.35 | -1.40 | -1.59 | -2.10 | -1.84 | -1.61 | -21.35 | -14.20 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.86x | 0.78x | 0.58x | 0.87x | 1.00x | 0.97x | 1.19x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BOLT Key Ratios
Bolt Biotherapeutics, Inc. (BOLT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -135.83% | -41.79% | -48.69% | -74.28% | -79.75% | -100.9% |
Return on Invested Capital (ROIC) | - | - | -94.37% | -31.36% | -37.23% | -55.52% | -45.99% | -56.6% |
Gross Margin | 100% | -17370.56% | -5904.37% | -1176.37% | -681.39% | 100% | 80.62% | 96.88% |
Net Margin | -14180% | -26289.18% | -7824.68% | -1537.76% | -878.58% | -820.78% | -433.74% | -455.15% |
Debt / Equity | - | - | 0.10x | 0.13x | 0.18x | 0.44x | 0.87x | 1.13x |
FCF Conversion | 0.86x | 0.78x | 0.58x | 0.87x | 1.00x | 0.97x | 1.19x | 0.90x |
Revenue Growth | - | 7.44% | 445.45% | 354.68% | 37.48% | -2.36% | 0.07% | 78.64% |
Related:BOLT Dividend History·BOLT Revenue History·BOLT Price History·BOLT P/E History·BOLT Financial Ratios·BOLT Institutional Holders
BOLT SEC Filings & Documents
Bolt Biotherapeutics, Inc. (BOLT) SEC filings — annual & quarterly reports (10-K, 10-Q)
BOLT Frequently Asked Questions
Bolt Biotherapeutics, Inc. (BOLT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bolt Biotherapeutics, Inc. (BOLT) reported $6.5M in revenue for fiscal year 2025.
Bolt Biotherapeutics, Inc. (BOLT) grew revenue by 0.1% over the past year. Growth has been modest.
Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $29.6M for fiscal year 2025.
Dividend & Returns
Bolt Biotherapeutics, Inc. (BOLT) has a return on equity (ROE) of -79.7%. Negative ROE indicates the company is unprofitable.
Bolt Biotherapeutics, Inc. (BOLT) had negative free cash flow of $26.6M in fiscal year 2025, likely due to heavy capital investments.